Hormone Therapy and Breast Cancer: Relative Risk, Absolute Risk, the Type of Hormone and the Decision a Woman in Her Forties or Fifties Is Really Making

Of all the questions a woman asks about menopausal hormone therapy, one comes up first and returns most often: does it cause breast cancer? The question is reasonable. The answer, in the way it is usually heard, is also misleading, because the real answer depends on which hormone, for how long, starting when, in which woman and measured in which way.

This guide, from the team behind Liondale's menopause and longevity medicine work in New York, is written for women who are weighing hormone therapy and want to understand the evidence without panic or promotion. It covers where the fear came from, why relative and absolute risk tell different stories, how estrogen alone differs from estrogen with a progestogen, what timing does and does not change, what the bioidentical label can and cannot tell you, and how to approach the decision with a physician.

It is general information, not individual medical advice, and anyone with a personal history of breast cancer or a strong family history needs an individualized conversation with their own doctors.

Where the fear came from

In the 1990s and before, hormone therapy was widely prescribed, often with the belief that it would protect the heart and extend healthy life. Observational studies had suggested benefits. The Women's Health Initiative, a large randomized trial, set out to test them.

In 2002, one arm of that trial, testing a combination of conjugated equine estrogen with a synthetic progestin called medroxyprogesterone acetate, was stopped early. The investigators reported a small increase in invasive breast cancer, along with increases in heart disease, stroke and blood clots. Headlines declared that hormone therapy was dangerous. Prescriptions fell sharply within months, and many women who were struggling with symptoms stopped treatment or never began.

In the years since, researchers reanalyzed the data and followed participants for longer. The picture became more nuanced, in ways that matter for the individual woman. But the first message, simple and frightening, had already reached millions of people, and it still shapes how many hear the question today.

Relative risk versus absolute risk

The most important idea for reading any headline about hormone therapy and cancer is the difference between relative and absolute risk.

Relative risk compares two groups. If a study says a treatment increases risk by 25 percent, that is a relative number. It tells you the risk is one and a quarter times the baseline.

Absolute risk tells you how many people are affected. If the baseline risk over a certain period is 4 in 1,000 and a 25 percent increase raises it to 5 in 1,000, the absolute increase is 1 in 1,000. The relative number sounds large, and the absolute number is small.

Neither number is wrong. They answer different questions. A relative figure is useful to compare treatments, and an absolute figure is useful to decide how much a risk matters in your own life. A woman deciding about hormone therapy needs both, and she needs them for her own baseline, not for the average woman.

Baseline matters. A woman's own risk of breast cancer depends on age, family history, breast density, reproductive history, body weight, alcohol use, prior biopsies and other factors. A modest relative increase applied to a high baseline is a larger absolute change than the same increase applied to a low one. This is why a blanket statement about hormone therapy and breast cancer, in either direction, is never enough.

Putting the numbers in everyday terms

The reanalyses of the Women's Health Initiative showed that in women who took estrogen plus a synthetic progestin for several years, there was a small increase in the number of breast cancers diagnosed. Expressed in absolute terms, this was on the order of a few additional cases per 10,000 women per year of use. That figure is small, but it is not zero, and it rose with duration of use.

For comparison, other common exposures carry a similar or larger increase in breast cancer risk. Alcohol consumption, even at moderate levels, is associated with increased risk. Excess body weight after menopause is associated with increased risk. Physical inactivity contributes. The comparison does not make the hormone-related risk disappear, but it places it in context. For many women, modifiable lifestyle factors have a similar or larger impact on breast cancer risk than hormone therapy used for symptoms.

This is not meant to minimize the issue. Women have every right to treat a small increase in cancer risk as significant. The goal is to make sure the number a woman worries about is the real number, not the one from a headline.

Finding your own baseline

Because absolute risk depends on the starting point, the most useful number in this whole discussion is your own baseline. Clinicians estimate it with tools that combine age, family history, reproductive history, breast density, prior biopsy results and other factors. Different tools give somewhat different answers, and none is perfect, but they provide a structured estimate that is far more useful than a general statement.

If you have not had a risk assessment, it is reasonable to ask for one before deciding. A woman whose ten year risk is modest may hear the same relative increase very differently from a woman whose risk is high. It is also worth asking how breast density was measured and whether your imaging reports mention it, since density is one of the most informative and most overlooked pieces of the picture.

Standard panels rarely tell the whole story, and the practice explains how standard labs compare with precision diagnostics for readers who want that wider view. Your baseline can change. Risk estimates shift with age, weight, new family history and the results of each screening round. Treat the number as a living estimate, not a verdict.

Estrogen alone is not the same as estrogen plus a progestogen

One of the most important findings from the Women's Health Initiative is also one of the least known. The trial had two main arms. In women who had a uterus, estrogen was given together with a progestin, because estrogen alone increases the risk of uterine cancer. In women who had had a hysterectomy, estrogen was given alone.

The results differed. In the estrogen-alone arm, there was no increase in breast cancer risk during the main trial period, and in some analyses there was a lower rate of breast cancer in the estrogen group. Longer-term follow-up has continued to show no increase, and has suggested a possible reduction, though the finding is debated and the reasons are not fully understood.

In the combined arm, the risk of breast cancer was increased. This led researchers to ask whether the progestogen component, or the specific synthetic progestin used, was driving the difference.

That question is still being studied, but it is clear that it is incorrect to speak of hormone therapy as a single exposure. Estrogen alone and estrogen with a progestogen appear to behave differently with respect to breast tissue.

Which progestogen? The unresolved question

Women with a uterus need a progestogen alongside estrogen to protect the lining of the uterus. The medication used in the Women's Health Initiative, medroxyprogesterone acetate, is a synthetic progestin. Others in use include norethindrone and micronized progesterone, which is chemically identical to the progesterone the body makes.

Observational studies from Europe, especially French cohorts, have suggested that estrogen combined with micronized progesterone may carry a lower breast cancer risk than estrogen combined with certain synthetic progestins. These studies are not randomized trials, and they can be confounded by differences between the women who receive different regimens. The evidence is encouraging but not conclusive.

The honest summary is that the type of progestogen may matter, that micronized progesterone is considered by many specialists to be a reasonable choice and that the question has not been settled by the kind of large randomized trial that would settle it. Women should be wary of anyone who claims certainty in either direction.

What about bioidentical hormones?

The term bioidentical describes hormones that are chemically identical to those the body produces. Estradiol and micronized progesterone are bioidentical, and both are available as FDA-approved prescription products. The term can also describe custom compounded preparations, which are mixed by a pharmacy to a prescriber's specification.

Liondale has written about bioidentical versus synthetic hormones and about the reasons some patients prefer a bioidentical approach. For the breast cancer question, the key point is narrower. Being bioidentical does not by itself prove that a hormone is safer for breast tissue. Estradiol is estrogen, whatever its source. The claim that natural or bioidentical hormones carry no cancer risk is not supported by evidence, and patients should be skeptical when they hear it.

Compounded products add a separate concern: they are not individually FDA reviewed for safety, dose consistency or purity in the way approved products are. Some patients and physicians accept that trade-off for flexibility. It is a decision to make with open eyes.

Who is prescribing, and how it is monitored

The quality of a hormone decision depends on the quality of the follow-up. Hormone therapy is not a prescription to be written once and forgotten. It calls for baseline evaluation, a dose adjusted to symptoms and labs where appropriate, and a schedule of reassessment. The practice has written about the difference between physician-led and nurse-led longevity clinics, and for a decision involving cancer risk, a patient is entitled to ask who is making the medical judgments and how closely they will be monitoring.

Monitoring also means attention to symptoms that might signal a problem: unexpected vaginal bleeding, breast changes, new severe headaches, leg swelling or chest pain. Women should know in advance what to report and how to reach the practice.

Delivery route: pills, patches, gels and pellets

The route by which estrogen enters the body affects other risks, particularly blood clots and stroke. Oral estrogen passes through the liver and is associated with a higher risk of clots than transdermal estrogen delivered through a patch, gel or cream. This does not directly answer the breast cancer question, but it affects the overall risk and benefit balance and is one reason many clinicians favor transdermal estradiol for appropriate patients.

For breast cancer specifically, the evidence on whether route matters is limited. Large datasets suggest that risk patterns for transdermal and oral therapy are similar, but data are less robust. Pellets, which are implanted under the skin, have been less studied, and their dosing can be harder to adjust.

The practical point is that choosing a route is part of the risk conversation, and the answer for one woman may differ from another.

Timing and duration

Two questions about timing are worth separating.

The first is when therapy begins relative to menopause. The timing hypothesis, supported by analyses of the Women's Health Initiative and other studies, proposes that hormone therapy started within about ten years of menopause, or before age 60, has a more favorable balance of effects on the heart and brain than therapy started later. This is largely a cardiovascular and cognitive question, but it influences the overall risk and benefit calculation, because the benefits are weighed against breast cancer risk.

The second is how long therapy continues. In studies of combined therapy, breast cancer risk tends to increase with years of use and tends to decline after stopping, though the decline may take some time. For short-term use, say a few years for symptom relief, the increase in absolute risk is small. For longer use, it becomes more relevant, and the decision about continuing deserves regular review.

For this reason, many guidelines suggest using the lowest effective dose for the shortest time consistent with treatment goals, while recognizing that for some women, particularly those with persistent severe symptoms, longer therapy may be appropriate. The decision to continue should be made yearly, with updated information about the woman's health and risks.

Breast density, family history and other individual factors

A woman's own risk profile changes the conversation. Dense breasts are associated with both higher baseline breast cancer risk and greater difficulty detecting cancer on mammograms. A family history of breast cancer, especially in a first-degree relative at a young age, raises baseline risk. Certain inherited gene variants, such as BRCA1 and BRCA2, raise it substantially.

These factors do not automatically rule out hormone therapy, but they change the weighing. A woman with a very high baseline risk may decide that even a small relative increase is not acceptable. Another may decide that severe symptoms or bone loss justify the risk with careful surveillance. Both are reasonable decisions, but they must be based on the woman's own numbers.

Women with a personal history of breast cancer are in a separate category. Systemic hormone therapy is generally not recommended after hormone-sensitive breast cancer, and decisions about symptom relief in this group are made with oncology input. Non-hormonal options exist and are discussed below.

Screening matters whatever you decide

Whether or not a woman takes hormone therapy, regular breast cancer screening is important. Recommendations vary by guideline and individual risk, but typically include mammography at intervals appropriate to age and risk, and clinical attention to any new breast changes. Women on hormone therapy should keep up with screening and should report new lumps, nipple changes or skin changes promptly.

Hormone therapy can increase breast density in some women, which may affect mammogram interpretation, so telling the imaging team about hormone use is helpful. For women with dense breasts or elevated risk, a physician may discuss additional imaging.

A comprehensive approach to risk looks at more than hormones, and the practice frames this as a shift from sick care to true health care. The practice has described its broader approach to longevity in articles on longevity labs and biomarkers and on precision diagnostics, which give context for how hormone decisions fit with other health data.

Weight, alcohol, activity and the risks you control

Most of the lifestyle factors linked to breast cancer risk are within a woman's influence, and they interact with hormone decisions. Alcohol shows a consistent dose-related association with risk. Excess body fat after menopause raises circulating estrogen, because fat tissue produces it, and is associated with higher risk. Regular physical activity is associated with lower risk. Smoking adds to many other health risks.

Muscle also matters in midlife. Practice articles on sarcopenic obesity and muscle loss explain why maintaining lean mass is important for metabolic health, which relates to many conditions that cluster around menopause. None of this is a substitute for medical therapy, but lifestyle factors can shift the overall risk balance as much as the decision about hormones, and they are available to women regardless of what they choose.

When symptoms are not only menopause

Hot flashes, poor sleep, fatigue, low mood and brain fog are classic menopausal complaints, and they overlap with other conditions, including thyroid disease, anemia, sleep apnea and depression. Attributing everything to menopause can delay the right diagnosis. The practice's article on thyroid labs beyond TSH shows why a thorough workup matters before assuming a cause.

This matters for the hormone decision because treating the wrong problem leaves symptoms in place and adds exposure without benefit. A physician who looks at the whole picture before prescribing is protecting the patient from that outcome.

The benefits side of the ledger

A fair decision requires weighing benefits as well as risks, and benefits are real for many women.

Hormone therapy is the most effective treatment for hot flashes and night sweats, which can seriously impair sleep, mood and work. It treats genitourinary symptoms such as vaginal dryness and pain with intercourse, and local low-dose vaginal estrogen can do so with minimal systemic absorption. It helps prevent bone loss and reduces the risk of fractures. For some women, it improves sleep, mood and quality of life.

There is also continuing research on possible effects on brain and heart health, which is discussed in Liondale's article on hormone replacement therapy for women in their 40s and Alzheimer's prevention. That evidence is evolving, and it should be read as promising but not definitive.

The benefits have to be weighed against risks in light of the woman's symptoms, age, time since menopause, health history and preferences. For a woman with severe symptoms and low baseline risk, the balance may favor treatment. For a woman with mild symptoms and high baseline breast cancer risk, it may not.

Regulatory changes and what they mean

Regulatory language about hormone therapy has shifted. Prescribing information for these products has long carried boxed warnings about cardiovascular disease, breast cancer and dementia, based on the original trial findings. In late 2025, the FDA announced changes to remove boxed warnings from many menopausal hormone therapy labels, reflecting a reassessment of the evidence, while risk information remains in the labeling.

What this means for a patient is limited but worth noting. The label change does not mean there is no risk. It reflects a view that the original warnings overstated certain risks for many women, particularly those who start therapy near menopause. It does not replace an individual risk discussion. Readers should look to current guidance from their physician and professional societies for the latest position.

Two myths worth retiring

The first myth is that hormone therapy is either completely safe or categorically dangerous. Both claims are too simple. It has real benefits for many women and real, though small and variable, risks. Any source that presents only one side is selling something, whether fear or reassurance.

The second myth is that natural means risk free. Plant-derived and bioidentical hormones are still hormones, and they act on the same receptors. A product is not safe because of where it comes from. It is safe or not safe according to what it does in the body, at what dose, in which patient and for how long. This applies equally to prescription products and to over-the-counter supplements marketed for menopause, some of which contain plant compounds with estrogen-like activity that have not been studied for breast safety.

Letting go of both myths makes the conversation more honest, and it puts the decision back where it belongs: in the details of the individual woman's health.

How to talk about this with family and friends

Women often hear strong opinions from relatives and friends, many of them shaped by a story: a mother who took hormones and developed cancer, a friend who felt transformed by treatment. Stories are powerful, and they are not data. A relative's cancer may have been unrelated to hormones or may have been influenced by her own risk factors, and a friend's good experience does not guarantee yours.

It can help to say that you are gathering information and making the decision with your doctor, and that you appreciate their concern. Keeping the conversation about your own numbers, instead of about the general question, tends to lower the temperature.

Stopping, tapering and changing course

Starting hormone therapy is not irreversible. Women can reduce the dose, change the route, switch the progestogen or stop. Some women stop abruptly and find symptoms return, while others taper gradually. Neither approach is universally right, and the decision depends on why therapy was started and how the woman feels.

If symptoms return after stopping, it does not mean the therapy was a mistake, and it does not mean it must be resumed. It means the underlying transition is still going on. Some women restart at a lower dose, while others turn to non-hormonal options. A good physician treats this as a normal part of the process and not a failure.

Non-hormonal options

For women who decide against hormone therapy, or for whom it is not appropriate, there are non-hormonal choices. Certain antidepressants in low doses, gabapentin and newer non-hormonal medications designed for hot flashes can reduce symptoms for some women. Cognitive behavioral therapy and clinical hypnosis have evidence for reducing the bother of hot flashes. Lifestyle changes, including limiting alcohol, maintaining a healthy weight, regular exercise and cooling strategies, can help.

Vaginal moisturizers, lubricants and, in some cases, low-dose local therapies address genitourinary symptoms. Bone health can be supported through weight-bearing exercise, calcium and vitamin D as appropriate, and medications when indicated.

These options are not as effective as hormone therapy for severe vasomotor symptoms, but they are valuable alternatives, and presenting them honestly is part of respecting a woman's choice.

Testosterone and breast tissue

Some women also ask about testosterone, which Liondale discusses in its article on testosterone therapy for women in NYC. It is worth noting that testosterone for women is not FDA approved in the United States for menopausal symptoms, and its long-term effect on breast tissue has not been established in large trials. Data are limited, and the cautious position is that a woman with significant breast cancer risk should discuss it carefully with her physician.

What a thoughtful consultation looks like

A good consultation does not begin with a prescription. It begins with questions: what symptoms are you having and how severe are they, when did your periods stop, what is your personal and family history, have you had a mammogram, what is your breast density, what medications do you take and what are your concerns?

From there, the physician reviews labs where appropriate, assesses cardiovascular and bone health and discusses options. Liondale's menopause services and its piece on menopause and longevity medicine describe the practice's approach, and Dr. Lionel Bissoon, DO, works with patients as part of a concierge model described in the practice's overview of concierge medicine.

A good plan includes a defined starting dose, a schedule for reassessment, screening recommendations and an agreement that the decision can be revisited. It is not a permanent commitment. Women can start, adjust, pause and stop as their circumstances change.

Questions worth asking your own doctor

A short list can make an appointment more productive. What is my personal baseline risk of breast cancer, and how was it estimated? Would I be taking estrogen alone or with a progestogen, and which one? How does the route of delivery affect my risks? What is the lowest dose that would work for me? How often will we review the decision? What screening do I need? What are my non-hormonal options if I decide not to proceed?

You can also ask what evidence supports each recommendation, and how current it is. A physician who welcomes those questions is one worth working with.

The decision in its real shape

The decision about hormone therapy is not a verdict on whether it is safe. It is a trade-off, personal to each woman, between symptom relief and quality of life on one side, and a small, variable and partly uncertain increase in some risks on the other. For some women, the balance favors treatment. For others, it does not. For many, it changes over time.

What a woman deserves is accurate numbers, a clear explanation of what is known and unknown, and a physician who respects her choice. Fear and enthusiasm are both poor guides. Information is a better one.

Frequently Asked Questions

Does hormone therapy cause breast cancer?

It depends on the type. In large trials, estrogen plus a synthetic progestin was associated with a small increase in breast cancer risk, while estrogen alone in women without a uterus did not show an increase during the main trial.

What is the difference between relative and absolute risk?

Relative risk compares two groups, while absolute risk is the number of people actually affected. A large relative increase on a small baseline can be a small absolute change.

Is estrogen alone safer for breast tissue than combined therapy?

In the Women's Health Initiative, estrogen alone did not increase breast cancer risk, while combined therapy did. Estrogen alone is only used in women who have had a hysterectomy.

Does micronized progesterone lower the risk?

Some observational studies suggest it may carry a lower risk than certain synthetic progestins, but this has not been proven in randomized trials.

Are bioidentical hormones safer for breast cancer?

Not proven. Bioidentical estradiol is still estrogen, and there is no good evidence that bioidentical hormones eliminate breast cancer risk.

Does the delivery route matter for breast cancer risk?

Route clearly affects clot risk, with transdermal estrogen generally favored, but evidence for breast cancer differences is limited.

How long can I take hormone therapy?

Guidelines favor the lowest effective dose for the shortest time that meets your goals, with yearly review. Some women with persistent symptoms continue longer after discussing risks.

Does risk go away after I stop?

In studies, risk associated with combined therapy tends to decline after stopping, though not necessarily immediately.

Should I still get mammograms on hormone therapy?

Yes. Screening remains important, and you should tell the imaging team you use hormones since therapy can affect breast density.

Can I take hormone therapy with a family history of breast cancer?

It depends on your individual risk. Some women with a family history still choose therapy after careful discussion, while others do not, and your own numbers should guide the decision.

What if I have had breast cancer?

Systemic hormone therapy is generally not recommended after hormone-sensitive breast cancer. Non-hormonal options and oncology guidance are the starting point.

What can I do if I decide not to take hormones?

Non-hormonal medications, cognitive behavioral therapy, lifestyle changes, vaginal moisturizers and local therapies can relieve symptoms for many women.

This page was written and medically reviewed by Lionel Bissoon, D.O., founder of Liondale Medical. Dr. Bissoon is a board-certified osteopathic physician specializing in anti-aging and concierge medicine on the Upper West Side of Manhattan.

This content is for educational purposes only and does not constitute medical advice. Individual results may vary. Consult a qualified physician before beginning any new treatment.

Published October 20th, 2026